Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H32N2.2ClH |
Molecular Weight | 361.393 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.C(C1CC1)N2CC3CN(CC4CC4)CC(C2)C35CCCC5
InChI
InChIKey=NXXZICGFHYJPGE-UHFFFAOYSA-N
InChI=1S/C19H32N2.2ClH/c1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16;;/h15-18H,1-14H2;2*1H
Tedisamil is an antiarrhythmic with additional anti-ischaemic properties, which acts via potassium channel blockade. This drug can be categorised as a class III antiarrhythmic agent due to its effects of action potential and QT interval prolongation in these patients. Although tedisamil has been shown to be an effective anti-ischaemic agent, with Phase III trials for angina pectoris now completed, the company are now pursuing the use of tedisamil for the treatment of atrial fibrillation, for which tedisamil is still in Phase II/III clinical trials. The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted not to recommend approval for Solvay Pharmaceuticals’ investigational anti-arrhythmic drug Pulzium (Tedisamil) and asked the company to give the FDA more information.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Newer antiarrhythmic drugs. | 2001 May-Jun |
|
Do we need pharmacological therapy for atrial fibrillation in the ablation era? | 2006 Dec |
|
Approach to the asymptomatic patients with Brugada syndrome. | 2007 Apr 1 |
|
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? | 2008 Sep 22 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
132523-84-3
Created by
admin on Fri Dec 15 15:29:48 GMT 2023 , Edited by admin on Fri Dec 15 15:29:48 GMT 2023
|
PRIMARY | |||
|
11566690
Created by
admin on Fri Dec 15 15:29:48 GMT 2023 , Edited by admin on Fri Dec 15 15:29:48 GMT 2023
|
PRIMARY | |||
|
S5O682VL3K
Created by
admin on Fri Dec 15 15:29:48 GMT 2023 , Edited by admin on Fri Dec 15 15:29:48 GMT 2023
|
PRIMARY | |||
|
m10516
Created by
admin on Fri Dec 15 15:29:48 GMT 2023 , Edited by admin on Fri Dec 15 15:29:48 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD